ECSP22053394A - Inhibidores de sarm1 - Google Patents
Inhibidores de sarm1Info
- Publication number
- ECSP22053394A ECSP22053394A ECSENADI202253394A ECDI202253394A ECSP22053394A EC SP22053394 A ECSP22053394 A EC SP22053394A EC SENADI202253394 A ECSENADI202253394 A EC SENADI202253394A EC DI202253394 A ECDI202253394 A EC DI202253394A EC SP22053394 A ECSP22053394 A EC SP22053394A
- Authority
- EC
- Ecuador
- Prior art keywords
- sarm1
- sarm1 inhibitors
- inhibitors
- treating
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción proporciona compuestos y métodos útiles para inhibir SARM1 y/o tratar y/o prevenir la degeneración axonal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958178P | 2020-01-07 | 2020-01-07 | |
US202063065736P | 2020-08-14 | 2020-08-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22053394A true ECSP22053394A (es) | 2022-11-30 |
Family
ID=74505335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202253394A ECSP22053394A (es) | 2020-01-07 | 2022-07-07 | Inhibidores de sarm1 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230008433A1 (es) |
EP (1) | EP4087838A1 (es) |
KR (1) | KR20220164471A (es) |
CN (1) | CN115175900A (es) |
AU (2) | AU2021206651B2 (es) |
BR (1) | BR112022013388A2 (es) |
CA (1) | CA3163265A1 (es) |
CL (1) | CL2022001825A1 (es) |
CO (1) | CO2022009514A2 (es) |
CR (1) | CR20220375A (es) |
DO (1) | DOP2022000141A (es) |
EC (1) | ECSP22053394A (es) |
IL (1) | IL294507A (es) |
JO (1) | JOP20220167A1 (es) |
MX (1) | MX2022008395A (es) |
PE (1) | PE20230165A1 (es) |
TW (1) | TW202140437A (es) |
WO (1) | WO2021142006A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4192828A1 (en) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
CN116438171A (zh) | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
CA3226869A1 (en) | 2021-07-28 | 2023-02-02 | Rao Kolluri | Substituted pyridine derivatives as sarm1 inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
DE60332475D1 (de) * | 2002-10-30 | 2010-06-17 | Vertex Pharma | Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen |
AU2003300099A1 (en) * | 2003-01-02 | 2004-07-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta |
AR044519A1 (es) * | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
JP2007535551A (ja) * | 2004-04-28 | 2007-12-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Rockおよび他のプロテインキナーゼの阻害剤として有用な組成物 |
WO2006065946A1 (en) * | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
JP5244591B2 (ja) * | 2006-06-28 | 2013-07-24 | あすか製薬株式会社 | ピリジルイソオキサゾール誘導体 |
CN101516874A (zh) * | 2006-09-21 | 2009-08-26 | 诺瓦提斯公司 | 用于治疗细胞因子介导的疾病的吡咯衍生物 |
WO2009080705A2 (en) * | 2007-12-20 | 2009-07-02 | Novartis Ag | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
US8940771B2 (en) * | 2007-12-20 | 2015-01-27 | Novartis Ag | Organic compounds |
US8785468B2 (en) * | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
RU2570907C2 (ru) * | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
JP7044789B2 (ja) | 2016-09-24 | 2022-03-30 | ワシントン・ユニバーシティ | Sarm1 nadアーゼ活性の阻害剤およびその使用 |
TW201833087A (zh) * | 2016-12-09 | 2018-09-16 | 美商維泰克斯製藥公司 | 用於減少非常長鏈脂肪酸含量之1,3-取代吡唑化合物 |
MA52812A (fr) * | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
-
2021
- 2021-01-06 TW TW110100350A patent/TW202140437A/zh unknown
- 2021-01-06 AU AU2021206651A patent/AU2021206651B2/en active Active
- 2021-01-06 EP EP21703092.3A patent/EP4087838A1/en active Pending
- 2021-01-06 IL IL294507A patent/IL294507A/en unknown
- 2021-01-06 WO PCT/US2021/012333 patent/WO2021142006A1/en active Application Filing
- 2021-01-06 MX MX2022008395A patent/MX2022008395A/es unknown
- 2021-01-06 CA CA3163265A patent/CA3163265A1/en active Pending
- 2021-01-06 JO JOP/2022/0167A patent/JOP20220167A1/ar unknown
- 2021-01-06 CN CN202180019643.9A patent/CN115175900A/zh active Pending
- 2021-01-06 CR CR20220375A patent/CR20220375A/es unknown
- 2021-01-06 KR KR1020227027204A patent/KR20220164471A/ko unknown
- 2021-01-06 BR BR112022013388A patent/BR112022013388A2/pt unknown
- 2021-01-06 PE PE2022001414A patent/PE20230165A1/es unknown
- 2021-08-17 US US17/404,523 patent/US20230008433A1/en active Pending
-
2022
- 2022-07-05 CL CL2022001825A patent/CL2022001825A1/es unknown
- 2022-07-05 DO DO2022000141A patent/DOP2022000141A/es unknown
- 2022-07-06 CO CONC2022/0009514A patent/CO2022009514A2/es unknown
- 2022-07-07 EC ECSENADI202253394A patent/ECSP22053394A/es unknown
-
2024
- 2024-02-06 AU AU2024200703A patent/AU2024200703A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20230165A1 (es) | 2023-02-01 |
EP4087838A1 (en) | 2022-11-16 |
IL294507A (en) | 2022-09-01 |
BR112022013388A2 (pt) | 2022-09-20 |
AU2021206651A1 (en) | 2022-07-14 |
CA3163265A1 (en) | 2021-07-15 |
DOP2022000141A (es) | 2022-10-16 |
AU2021206651B2 (en) | 2024-02-22 |
WO2021142006A1 (en) | 2021-07-15 |
CO2022009514A2 (es) | 2022-10-21 |
MX2022008395A (es) | 2022-09-26 |
AU2024200703A1 (en) | 2024-02-29 |
CR20220375A (es) | 2022-09-22 |
US20230008433A1 (en) | 2023-01-12 |
TW202140437A (zh) | 2021-11-01 |
CL2022001825A1 (es) | 2023-06-02 |
KR20220164471A (ko) | 2022-12-13 |
CN115175900A (zh) | 2022-10-11 |
JOP20220167A1 (ar) | 2023-01-30 |
JP2023510743A (ja) | 2023-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP23012981A (es) | Inhibidores de sarm1 | |
ECSP22053394A (es) | Inhibidores de sarm1 | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
BR112018017086A2 (pt) | derivados de pirrolidina espiro-condensada como inibidores de enzimas desubiquitilantes (dub) | |
MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
WO2020252229A3 (en) | Inhibitors of sarm1 | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
BR112015023207A2 (pt) | uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase | |
PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
WO2018195110A8 (en) | Regulation of ran translation by pkr and eif2a-p pathways | |
PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
BR112018068027A2 (pt) | método para tratar câncer em um paciente e composição farmacêutica | |
MX2020009147A (es) | Moduladores de la expresion de irf4. | |
CL2021001246A1 (es) | Moduladores de expresión irf5. | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
MX2021006326A (es) | Inhibidores de pcna. | |
UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
BR112022005895A2 (pt) | Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
CO2019001402A2 (es) | Método para prevenir o tratar la pérdida de la audición | |
AR117079A1 (es) | Moduladores de la expresión de foxp3 | |
BR112024001180A2 (pt) | Composições e métodos para tratamento do melanoma |